Search

Your search keyword '"Kapiris, Matthaios"' showing total 9 results
Start Over Author "Kapiris, Matthaios"
9 results on '"Kapiris, Matthaios"'

1. Update on the prognostic value of a novel immune-related toxicity grading system (OST score) in patients with advanced solid tumours treated with immune checkpoint inhibitors (ICI).

Author

Kapiris, Matthaios, primary, Santaolalla, Aida, additional, Bratsos, Sosipatros, additional, Guhnam, Sundeep, additional, McDonald, Louisa, additional, Fitzpatrick-Greening, Mary, additional, Muhith, Moe, additional, Wu, Yin, additional, Georgiou, Alexandros, additional, Josephs, Debra Hannah, additional, Sarker, Debashis, additional, and Cope, Andrew, additional

Published
2024
Full Text
View/download PDF

3. Non-Small Cell Lung Cancer (NSCLC) in Young Adults, Age < 50, Is Associated with Late Stage at Presentation and a Very Poor Prognosis in Patients That Do Not Have a Targeted Therapy Option: A Real-World Study

Author

Hughes, Daniel Johnathan, primary, Kapiris, Matthaios, additional, Podvez Nevajda, Andreja, additional, McGrath, Harriet, additional, Stavraka, Chara, additional, Ahmad, Shahreen, additional, Taylor, Benjamin, additional, Cook, Gary J. R., additional, Ghosh, Sharmistha, additional, Josephs, Debra, additional, Pintus, Elias, additional, Gennatas, Spyridon, additional, Bille, Andrea, additional, Ryanna, Kimuli, additional, Santis, George, additional, Montes, Ana, additional, Van Hemelrijck, Mieke, additional, Karapanagiotou, Eleni, additional, Smith, Daniel, additional, Spicer, James, additional, and Georgiou, Alexandros, additional

Published
2022
Full Text
View/download PDF

4. Effect of peri-operative chemotherapy regimen on survival in the treatment of locally advanced oesophago-gastric adenocarcinoma – A comparison of the FLOT and ‘MAGIC’ regimens

Author

Moore, Jonathan L., primary, Kumar, Sacheen, additional, Santaolalla, Aida, additional, Patel, Pranav H., additional, Kapiris, Matthaios, additional, Van Hemelrijck, Mieke, additional, Maisey, Nick, additional, Hill, Mark, additional, Lagergren, Jesper, additional, Gossage, James A., additional, Kelly, Mark, additional, Chaudry, Asif, additional, Allum, William H., additional, Baker, Cara R., additional, Cunningham, David, additional, Davies, Andrew R., additional, Jacques, A., additional, Griffin, N., additional, Goh, V., additional, Ngan, S., additional, Owczarczyk, K., additional, Lumsden, A., additional, Qureshi, A., additional, Deere, H., additional, Green, M., additional, Chang, F., additional, Mahadeva, U., additional, Gill-Barman, B., additional, George, S., additional, Ong, M., additional, Waters, J., additional, Cominos, M., additional, Sevitt, T., additional, Hynes, O., additional, Tham, G., additional, Bott, R.K., additional, Dunn, J.M., additional, and Zeki, S.S., additional

Published
2022
Full Text
View/download PDF

7. Subcutaneous Trastuzumab Combined with Pertuzumab and Docetaxel as First-line Treatment of Advanced HER2-positive Breast Cancer

Author

STEFANOU, DIMITRA, primary, KOKKALI, STEFANIA, additional, TRIPODAKI, ELLI-SOPHIA, additional, DRIZOU, MARIA, additional, MAGOU, ELPIDA, additional, ZYLIS, DIMOSTHENIS, additional, PREVEZANOU, MARIA, additional, KAPIRIS, MATTHAIOS, additional, NASI, DESPOINA, additional, NTOKOU, ANNA, additional, DEDE, MARY, additional, and ARDAVANIS, ALEXANDROS, additional

Published
2018
Full Text
View/download PDF

9. Biweekly Gemcitabine/Nab-Paclitaxel as First-line Treatment for Advanced Pancreatic Cancer.

Author

Kokkali S, Tripodaki ES, Drizou M, Stefanou D, Magou E, Zylis D, Kapiris M, Nasi D, Georganta C, and Ardavanis A

Subjects
Aged, Aged, 80 and over, Albumins administration & dosage, Antineoplastic Combined Chemotherapy Protocols adverse effects, Deoxycytidine administration & dosage, Deoxycytidine analogs & derivatives, Drug Administration Schedule, Female, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Neoplasm Metastasis, Neoplasm Staging, Paclitaxel administration & dosage, Pancreatic Neoplasms mortality, Retrospective Studies, Treatment Outcome, Gemcitabine, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Pancreatic Neoplasms drug therapy, Pancreatic Neoplasms pathology
Abstract

Background/aim: During recent years, a survival advantage was reported for first-line treatment of advanced pancreatic cancer with two new regimens, FOLFIRINOX and gemcitabine/nab-paclitaxel, over gemcitabine monotherapy. Gemcitabine/nab-paclitaxel administration on days 1, 8 and 15 of a 4-week cycle is associated with some practical disadvantages. We adopted a biweekly regimen with the same dose density., Patients and Methods: Patients with Eastern Cooperative Oncology Group performance status 0-2 diagnosed with advanced histologically or cytologically confirmed pancreatic cancer and no prior treatment were included in the study. Study combination included 1.5 g/m 2 gemcitabine and 175 mg/m 2 nab-paclitaxel given every 2 weeks. Survival analysis was performed using the Kaplan-Meier method., Results: Forty-six patients were treated with this regimen. Adverse events were similar to those of the original regimen. Median progression-free and overall survival were 5 and 10 months, respectively., Conclusion: Biweekly gemcitabine/nab-paclitaxel seems to have a similar safety and efficacy profile as the original regimen., (Copyright© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results